Table 1 Classification of luminal breast cancer cases using data from central immunohistochemistry assays in the AMBER consortium
From: Frequency of breast cancer subtypes among African American women in the AMBER consortium
Subtype frequency, n (%) | Sensitivity for PAM50 subtype | Specificity for PAM50 subtype | Accuracy for PAM50 subtype | ||
|---|---|---|---|---|---|
HR/HER2 | |||||
Luminal A | HR+/HER2- | 606 (50) | 82% | 69% | 73% |
Luminal B | HR+/HER2+ | 140 (11) | 20% | 94% | 79% |
HR/HER2/combined grade | |||||
Luminal A | HR+/HER2-, low/intermediate grade | 448 (37) | 69% | 86% | 81% |
Luminal B | HR+/HER2+, or HR+/HER2-, high grade | 298 (24) | 64% | 85% | 81% |
HR/HER2/Ki67 | |||||
Luminal A | HR+/HER2-, low Ki67a | 420 (34) | 66% | 87% | 80% |
Luminal B | HR+/HER2+, or HR+/HER2-, high Ki67a | 326 (27) | 68% | 84% | 81% |
HR/Ki67 | |||||
Luminal A | HR+, low Ki67b | 453 (37) | 67% | 86% | 80% |
Luminal B | HR+, high Ki67b | 293 (24) | 68% | 85% | 82% |